in addition , revenue in 2011 benefited from higher sales of the company 's animal health products and from the launch of victrelis , a treatment for chronic hepatitis c. these increases were partially offset by lower sales of cozaar and hyzaar , treatments for hypertension , which lost patent protection in the united states in april 2010 and in a number of major european markets in march 2010 , as well as by lower sales of caelyx , subutex and suboxone as the company no longer has marketing rights to these products . revenue was also negatively affected by lower sales of vytorin , a cholesterol modifying medicine , temodar , a treatment for certain types of brain tumors , proquad , a pediatric combination vaccine to help protect against measles , mumps , rubella and varicella , and varivax , a vaccine to help prevent chickenpox ( varicella ) . in addition , as discussed below , the ongoing implementation of certain provisions of u.s. health care reform legislation during 2011 resulted in further increases in medicaid rebates and other impacts that reduced revenues . additionally , many countries in the european union ( the eu ) have undertaken austerity measures aimed at reducing costs in health care and have implemented pricing actions that negatively impacted sales in 2011. in april 2011 , merck and johnson & johnson ( j & j ) reached an agreement to amend the agreement governing the distribution rights to remicade and simponi . this agreement concluded the arbitration proceeding 42 j & j initiated in may 2009. under the terms of the amended distribution agreement , merck relinquished marketing rights for remicade and simponi to j & j in territories including canada , central and south america , the middle east , africa and asia pacific effective july 1 , 2011. merck retained exclusive marketing rights throughout europe , russia and turkey ( the retained territories ) . the retained territories represented approximately 70 % of merck 's 2010 revenue of $ 2.8 billion from remicade and simponi . in addition , beginning july 1 , 2011 , all profits derived from merck 's exclusive distribution of the two products in the retained territories are being equally divided between merck and j & j . j & j also received a one-time payment from merck of $ 500 million in april 2011. during 2011 , the company continued the advancement of drug candidates through its pipeline . victrelis , the company 's innovative oral medicine for the treatment of chronic hepatitis c , was approved by the u.s. food and drug administration ( the fda ) and the european commission ( the ec ) . the fda also approved juvisync , a new treatment for type 2 diabetes that combines the active ingredient in the glucose-lowering medication januvia with the cholesterol-lowering medication zocor . in addition , the ec approved zoely , a monophasic combined oral contraceptive tablet for use by women to prevent pregnancy . cubicin , an antibacterial agent with activity against methicillin-resistant staphylococcus aureus ( mrsa ) , for which the company has licensed development and distribution rights in japan , was approved for use in that country . in february 2012 , the fda approved janumet xr , a new treatment for type 2 diabetes that combines sitagliptin , which is the active component of januvia , with extended-release metformin in a once-daily formulation ; cosopt pf , merck 's preservative-free formulation of cosopt ophthalmic solution , indicated for the reduction of elevated intraocular pressure in appropriate patients with open-angle glaucoma or ocular hypertension ; and zioptan , a preservative-free prostaglandin analogue ophthalmic solution . the company also received additional indications for several of its existing products . during 2011 , the fda approved an expanded age indication for zostavax , a vaccine to help prevent shingles ( herpes zoster ) , to include adults ages 50 to 59. in addition , the fda approved sylatron for the adjuvant treatment of melanoma in patients with microscopic or gross nodal involvement . also , simponi received an indication in the eu for use in combination with methotrexate in adults with severe , active and progressive rheumatoid arthritis not previously treated with methotrexate , having been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function . in january 2012 , the fda approved the use of isentress , in combination with other antiretroviral medicines , for the treatment of hiv-1 infection in pediatric patients two years of age and older and weighing at least 10 kg . the company currently has two candidates under review with the fda : mk-8669 , ridaforolimus , for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy and mk-0653c , zetia ( ezetimibe ) combined with atorvastatin for the treatment of primary or mixed hyperlipidemia . mk-8669 is also under review in the eu . the company currently has 19 candidates in phase iii development and anticipates filing a new drug application ( nda ) with the fda with respect to certain of these candidates in 2012 including mk-4305 , suvorexant , an investigational treatment for insomnia ; mk-8616 , bridion , a medication for the reversal of certain muscle relaxants used during surgery ; and v503 , a nine-valent hpv vaccine . the company also anticipates filings in 2013 for , among others , mk-0822 , odanacatib , an investigational treatment for osteoporosis , and mk-0524a , tredaptive , which is under development for the treatment of atherosclerosis . merck continues to pursue opportunities that have the potential to drive both near- and long-term growth . during 2011 , the company completed a variety of transactions including the acquisition of inspire pharmaceuticals , inc. , a specialty pharmaceutical company focused on developing and commercializing ophthalmic products . story_separator_special_tag consumer care product sales outside the united states and canada , previously included in the pharmaceutical segment , are now included in the consumer care segment . segment disclosures for prior years have been recast on a comparable basis with 2011. sales worldwide sales totaled $ 48.0 billion in 2011 , an increase of 4 % compared with $ 46.0 billion in 2010. foreign exchange favorably affected global sales performance by 2 % . the revenue increase was driven largely by growth in januvia and janumet , singulair , isentress , gardasil , simponi , rotateq , zetia , pneumovax and bridion . in addition , revenue in 2011 benefited from higher sales of the company 's animal health products and from the launch of victrelis . these increases were partially offset by lower sales of cozaar and hyzaar which lost patent protection in the united states in april 2010 and in a number of major european markets in march 2010 , as well as by lower sales of caelyx , subutex and suboxone as the company no longer has marketing rights to these products . revenue was also negatively affected by lower sales of vytorin , temodar , proquad and varivax . in addition , as discussed above , the ongoing implementation of certain provisions of u.s. health care reform legislation during 2011 resulted in further increases in medicaid rebates and other impacts that reduced revenues . domestic sales were $ 20.5 billion in 2011 , an increase of 1 % compared with $ 20.2 billion in 2010. the domestic sales increase was driven by higher sales of singulair , januvia , gardasil , janumet , and isentress , as well as by the launch of victrelis . these increases were partially offset by lower sales of cozaar , hyzaar , vytorin , varivax and proquad . 47 foreign sales were $ 27.6 billion in 2011 , an increase of 7 % compared with $ 25.8 billion in 2010 driven by growth in japan and in the emerging markets . foreign exchange favorably affected foreign sales performance by 4 % in 2011. foreign sales growth reflects the strong performance of januvia , janumet , singulair , simponi , isentress , zetia and nasonex , as well as higher sales of animal health products , partially offset by lower sales of cozaar , hyzaar and temodar . foreign sales represented 57 % of total sales in 2011 and 56 % of total sales in 2010. while many of the company 's brands experienced positive growth trends in the eu during 2011 , the environment in the eu continues to be challenging . many countries have announced austerity measures , which include the implementation of pricing actions to reduce prices of generic and patented drugs . while the company is taking steps to mitigate the impact in the eu , the austerity measures have negatively affected the company 's revenue performance in 2011 and the company anticipates mid-single digit pricing pressures in 2012 across europe as well as from the biennial price reductions in japan . worldwide sales totaled $ 46.0 billion in 2010 compared with $ 27.4 billion in 2009. foreign exchange favorably affected global sales performance by 1 % . the revenue increase over 2009 was driven largely by incremental sales resulting from the inclusion of a full year of results in 2010 for legacy schering-plough products such as remicade , nasonex , temodar , pegintron and clarinex , as well as by the inclusion of a full year of results for merck/schering-plough partnership ( msp partnership ) products zetia and vytorin . prior to the merger , substantially all sales of zetia and vytorin were recognized by the msp partnership and the results of merck 's interest in the msp partnership were recorded in equity income from affiliates . as a result of the merger , the msp partnership became wholly owned by the company and therefore revenues from these products are now reflected in sales . additionally , the company recognized a full year of sales in 2010 from legacy schering-plough animal health and consumer care products . sales for 2009 only include revenue from legacy schering-plough and msp partnership products for the post-merger period through december 31 , 2009. also contributing to the sales increase was growth in januvia and janumet , isentress and singulair . these increases were partially offset by lower sales of cozaar , hyzaar , fosamax and fosamax plus d , and lower revenue from the company 's relationship with azlp . other products that experienced declines include gardasil and zocor . in addition , the implementation of certain provisions of u.s. health care reform legislation during 2010 resulted in increased medicaid rebates and other impacts that reduced revenues . 48 sales ( 1 ) of the company 's products were as follows : replace_table_token_9_th ( 1 ) sales of legacy schering-plough products in 2009 are included only for the post-merger period . in addition , prior to the merger , substantially all sales of zetia and vytorin were recognized by the msp partnership and the results of merck 's interest in the msp partnership were recorded in equity income from affiliates . as a result of the merger , the msp partnership became wholly owned by the company ; accordingly , all sales of msp partnership products after the merger are reflected in the table above . sales of zetia and vytorin in 2009 reflect merck 's sales of these products in latin america which was not part of the msp partnership , as well as sales of these products for the post-merger period in 2009 . ( 2 ) these amounts do not reflect sales of vaccines sold in most major european markets through the company 's joint venture , sanofi pasteur msd , the results of which are reflected in equity income from affiliates . these amounts do , however , reflect supply sales to sanofi pasteur msd .

analysis of liquidity and capital resources merck 's strong financial profile enables it to fully fund research and development , focus on external alliances , support in-line products and maximize upcoming launches while providing significant cash returns to shareholders . selected data replace_table_token_15_th cash provided by operating activities was $ 12.4 billion in 2011 , $ 10.8 billion in 2010 and $ 3.4 billion in 2009. the increase in cash provided by operating activities in 2011 as compared with 2010 reflects increased results of operations , partially offset by a $ 500 million payment made to j & j as a result of the arbitration settlement , as well as net payments of approximately $ 465 million to the internal revenue service ( irs ) as a result of the conclusion of its examination of certain of merck 's federal income tax returns as discussed below . the increase in cash provided by operating activities in 2010 as compared with 2009 primarily reflects the inclusion of a full year of legacy schering-plough operations , as well as $ 4.1 billion of payments in 2009 into the vioxx settlement funds and a $ 660 million payment in 2009 made in connection with the previously disclosed settlement with the canada revenue agency ( cra ) . cash provided by operating activities continues to be the company 's primary source of funds to finance operating needs , capital expenditures , treasury stock purchases and dividends paid to shareholders . the global economic downturn and the sovereign debt issues , among other factors , have adversely impacted foreign receivables in certain european countries ( see note 7 to the consolidated financial statements ) . while the company 69 continues to receive payment on these receivables , these conditions have resulted in an increase in the average length of time it takes to collect accounts receivable outstanding thereby adversely affecting cash provided by operating activities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```analysis of liquidity and capital resources merck 's strong financial profile enables it to fully fund research and development , focus on external alliances , support in-line products and maximize upcoming launches while providing significant cash returns to shareholders . selected data replace_table_token_15_th cash provided by operating activities was $ 12.4 billion in 2011 , $ 10.8 billion in 2010 and $ 3.4 billion in 2009. the increase in cash provided by operating activities in 2011 as compared with 2010 reflects increased results of operations , partially offset by a $ 500 million payment made to j & j as a result of the arbitration settlement , as well as net payments of approximately $ 465 million to the internal revenue service ( irs ) as a result of the conclusion of its examination of certain of merck 's federal income tax returns as discussed below . the increase in cash provided by operating activities in 2010 as compared with 2009 primarily reflects the inclusion of a full year of legacy schering-plough operations , as well as $ 4.1 billion of payments in 2009 into the vioxx settlement funds and a $ 660 million payment in 2009 made in connection with the previously disclosed settlement with the canada revenue agency ( cra ) . cash provided by operating activities continues to be the company 's primary source of funds to finance operating needs , capital expenditures , treasury stock purchases and dividends paid to shareholders . the global economic downturn and the sovereign debt issues , among other factors , have adversely impacted foreign receivables in certain european countries ( see note 7 to the consolidated financial statements ) . while the company 69 continues to receive payment on these receivables , these conditions have resulted in an increase in the average length of time it takes to collect accounts receivable outstanding thereby adversely affecting cash provided by operating activities .
```    
 Suspicious Activity Report : in addition , revenue in 2011 benefited from higher sales of the company 's animal health products and from the launch of victrelis , a treatment for chronic hepatitis c. these increases were partially offset by lower sales of cozaar and hyzaar , treatments for hypertension , which lost patent protection in the united states in april 2010 and in a number of major european markets in march 2010 , as well as by lower sales of caelyx , subutex and suboxone as the company no longer has marketing rights to these products . revenue was also negatively affected by lower sales of vytorin , a cholesterol modifying medicine , temodar , a treatment for certain types of brain tumors , proquad , a pediatric combination vaccine to help protect against measles , mumps , rubella and varicella , and varivax , a vaccine to help prevent chickenpox ( varicella ) . in addition , as discussed below , the ongoing implementation of certain provisions of u.s. health care reform legislation during 2011 resulted in further increases in medicaid rebates and other impacts that reduced revenues . additionally , many countries in the european union ( the eu ) have undertaken austerity measures aimed at reducing costs in health care and have implemented pricing actions that negatively impacted sales in 2011. in april 2011 , merck and johnson & johnson ( j & j ) reached an agreement to amend the agreement governing the distribution rights to remicade and simponi . this agreement concluded the arbitration proceeding 42 j & j initiated in may 2009. under the terms of the amended distribution agreement , merck relinquished marketing rights for remicade and simponi to j & j in territories including canada , central and south america , the middle east , africa and asia pacific effective july 1 , 2011. merck retained exclusive marketing rights throughout europe , russia and turkey ( the retained territories ) . the retained territories represented approximately 70 % of merck 's 2010 revenue of $ 2.8 billion from remicade and simponi . in addition , beginning july 1 , 2011 , all profits derived from merck 's exclusive distribution of the two products in the retained territories are being equally divided between merck and j & j . j & j also received a one-time payment from merck of $ 500 million in april 2011. during 2011 , the company continued the advancement of drug candidates through its pipeline . victrelis , the company 's innovative oral medicine for the treatment of chronic hepatitis c , was approved by the u.s. food and drug administration ( the fda ) and the european commission ( the ec ) . the fda also approved juvisync , a new treatment for type 2 diabetes that combines the active ingredient in the glucose-lowering medication januvia with the cholesterol-lowering medication zocor . in addition , the ec approved zoely , a monophasic combined oral contraceptive tablet for use by women to prevent pregnancy . cubicin , an antibacterial agent with activity against methicillin-resistant staphylococcus aureus ( mrsa ) , for which the company has licensed development and distribution rights in japan , was approved for use in that country . in february 2012 , the fda approved janumet xr , a new treatment for type 2 diabetes that combines sitagliptin , which is the active component of januvia , with extended-release metformin in a once-daily formulation ; cosopt pf , merck 's preservative-free formulation of cosopt ophthalmic solution , indicated for the reduction of elevated intraocular pressure in appropriate patients with open-angle glaucoma or ocular hypertension ; and zioptan , a preservative-free prostaglandin analogue ophthalmic solution . the company also received additional indications for several of its existing products . during 2011 , the fda approved an expanded age indication for zostavax , a vaccine to help prevent shingles ( herpes zoster ) , to include adults ages 50 to 59. in addition , the fda approved sylatron for the adjuvant treatment of melanoma in patients with microscopic or gross nodal involvement . also , simponi received an indication in the eu for use in combination with methotrexate in adults with severe , active and progressive rheumatoid arthritis not previously treated with methotrexate , having been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function . in january 2012 , the fda approved the use of isentress , in combination with other antiretroviral medicines , for the treatment of hiv-1 infection in pediatric patients two years of age and older and weighing at least 10 kg . the company currently has two candidates under review with the fda : mk-8669 , ridaforolimus , for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy and mk-0653c , zetia ( ezetimibe ) combined with atorvastatin for the treatment of primary or mixed hyperlipidemia . mk-8669 is also under review in the eu . the company currently has 19 candidates in phase iii development and anticipates filing a new drug application ( nda ) with the fda with respect to certain of these candidates in 2012 including mk-4305 , suvorexant , an investigational treatment for insomnia ; mk-8616 , bridion , a medication for the reversal of certain muscle relaxants used during surgery ; and v503 , a nine-valent hpv vaccine . the company also anticipates filings in 2013 for , among others , mk-0822 , odanacatib , an investigational treatment for osteoporosis , and mk-0524a , tredaptive , which is under development for the treatment of atherosclerosis . merck continues to pursue opportunities that have the potential to drive both near- and long-term growth . during 2011 , the company completed a variety of transactions including the acquisition of inspire pharmaceuticals , inc. , a specialty pharmaceutical company focused on developing and commercializing ophthalmic products . story_separator_special_tag consumer care product sales outside the united states and canada , previously included in the pharmaceutical segment , are now included in the consumer care segment . segment disclosures for prior years have been recast on a comparable basis with 2011. sales worldwide sales totaled $ 48.0 billion in 2011 , an increase of 4 % compared with $ 46.0 billion in 2010. foreign exchange favorably affected global sales performance by 2 % . the revenue increase was driven largely by growth in januvia and janumet , singulair , isentress , gardasil , simponi , rotateq , zetia , pneumovax and bridion . in addition , revenue in 2011 benefited from higher sales of the company 's animal health products and from the launch of victrelis . these increases were partially offset by lower sales of cozaar and hyzaar which lost patent protection in the united states in april 2010 and in a number of major european markets in march 2010 , as well as by lower sales of caelyx , subutex and suboxone as the company no longer has marketing rights to these products . revenue was also negatively affected by lower sales of vytorin , temodar , proquad and varivax . in addition , as discussed above , the ongoing implementation of certain provisions of u.s. health care reform legislation during 2011 resulted in further increases in medicaid rebates and other impacts that reduced revenues . domestic sales were $ 20.5 billion in 2011 , an increase of 1 % compared with $ 20.2 billion in 2010. the domestic sales increase was driven by higher sales of singulair , januvia , gardasil , janumet , and isentress , as well as by the launch of victrelis . these increases were partially offset by lower sales of cozaar , hyzaar , vytorin , varivax and proquad . 47 foreign sales were $ 27.6 billion in 2011 , an increase of 7 % compared with $ 25.8 billion in 2010 driven by growth in japan and in the emerging markets . foreign exchange favorably affected foreign sales performance by 4 % in 2011. foreign sales growth reflects the strong performance of januvia , janumet , singulair , simponi , isentress , zetia and nasonex , as well as higher sales of animal health products , partially offset by lower sales of cozaar , hyzaar and temodar . foreign sales represented 57 % of total sales in 2011 and 56 % of total sales in 2010. while many of the company 's brands experienced positive growth trends in the eu during 2011 , the environment in the eu continues to be challenging . many countries have announced austerity measures , which include the implementation of pricing actions to reduce prices of generic and patented drugs . while the company is taking steps to mitigate the impact in the eu , the austerity measures have negatively affected the company 's revenue performance in 2011 and the company anticipates mid-single digit pricing pressures in 2012 across europe as well as from the biennial price reductions in japan . worldwide sales totaled $ 46.0 billion in 2010 compared with $ 27.4 billion in 2009. foreign exchange favorably affected global sales performance by 1 % . the revenue increase over 2009 was driven largely by incremental sales resulting from the inclusion of a full year of results in 2010 for legacy schering-plough products such as remicade , nasonex , temodar , pegintron and clarinex , as well as by the inclusion of a full year of results for merck/schering-plough partnership ( msp partnership ) products zetia and vytorin . prior to the merger , substantially all sales of zetia and vytorin were recognized by the msp partnership and the results of merck 's interest in the msp partnership were recorded in equity income from affiliates . as a result of the merger , the msp partnership became wholly owned by the company and therefore revenues from these products are now reflected in sales . additionally , the company recognized a full year of sales in 2010 from legacy schering-plough animal health and consumer care products . sales for 2009 only include revenue from legacy schering-plough and msp partnership products for the post-merger period through december 31 , 2009. also contributing to the sales increase was growth in januvia and janumet , isentress and singulair . these increases were partially offset by lower sales of cozaar , hyzaar , fosamax and fosamax plus d , and lower revenue from the company 's relationship with azlp . other products that experienced declines include gardasil and zocor . in addition , the implementation of certain provisions of u.s. health care reform legislation during 2010 resulted in increased medicaid rebates and other impacts that reduced revenues . 48 sales ( 1 ) of the company 's products were as follows : replace_table_token_9_th ( 1 ) sales of legacy schering-plough products in 2009 are included only for the post-merger period . in addition , prior to the merger , substantially all sales of zetia and vytorin were recognized by the msp partnership and the results of merck 's interest in the msp partnership were recorded in equity income from affiliates . as a result of the merger , the msp partnership became wholly owned by the company ; accordingly , all sales of msp partnership products after the merger are reflected in the table above . sales of zetia and vytorin in 2009 reflect merck 's sales of these products in latin america which was not part of the msp partnership , as well as sales of these products for the post-merger period in 2009 . ( 2 ) these amounts do not reflect sales of vaccines sold in most major european markets through the company 's joint venture , sanofi pasteur msd , the results of which are reflected in equity income from affiliates . these amounts do , however , reflect supply sales to sanofi pasteur msd .

